Inpatient, Dose-Ranging Study of Staccato Alprazolam in Epilepsy With Predictable Seizure Pattern

Inclusion Criteria:

   1. Subject is able to provide, personally signed, and dated informed consent to
   participate in the study or will have a legally authorized representative sign the
   informed consent on his or her behalf before completing any study related procedures.

   2. Male or female ≥ 18 years of age.

   3. Has an established diagnosis of focal or generalized epilepsy or focal and generalized
   epilepsy with a documented history of predictable seizure episodes that includes at
   least one of the following:

      - Generalized seizure episodes starting with a flurry of absence seizures or
      myoclonic seizures with a minimum duration of 5 minutes

      - Episodes of a prolonged focal seizure with a minimum duration of 3 minutes

      - Episodes of multiple (≥2) seizures within a 2-hour time period

   4. Prior to randomization, has experienced ≥4 seizure episodes with predictable pattern
   during the last 4 weeks (qualification period) and no more than one week without a
   predictable seizure episode before entry into the in-patient unit.

   5. Female participants (if of child-bearing potential and sexually active) and male
   participants (if sexually active with a partner of child-bearing potential) who agree
   to use a medically acceptable and effective birth control method throughout the study
   and for 1 week following the end of the study. Medically acceptable methods of
   contraception that may be used by the participant and/or his/her partner include
   abstinence, birth control pills or patches, diaphragm with spermicide,intrauterine
   device (IUD), surgical sterilization, and progestin implant or injection. Prohibited
   methods include: the rhythm method, withdrawal, condoms alone, or diaphragm alone.

   6. Subject is able to comply by the requirements of the protocol, particularly the
   requirements and specific Institution policies during the in-clinic stay.

Exclusion Criteria:

   1. History or diagnosis of non-epileptic seizures (e.g. metabolic or pseudo-seizures).

   2. History of status epilepticus in the 6 months prior to Screening

   3. Has a progressive neurological disorder such as brain tumor, demyelinating disease, or
   degenerative central nervous system (CNS) disease that is likely to progress in the
   next 3 months

   4. Use of strong CYP 3A4 inhibitors; including azole antifungal agents (e.g.,
   etoconazole, itraconazole), nefazodone, fluvoxamine, cimetidine, HIV protease
   inhibitors (e.g., ritonavir)

   5. Has severe chronic cardio-respiratory disease

   6. History of HIV-positivity.

   7. Pregnant or breast-feeding.

   8. Clinically significant renal or hepatic insufficiency (hepatic transaminases >2 times
   the upper limit of normal (ULN) or creatinine ≥ 1.5 x ULN).

   9. History of acute narrow angle glaucoma, Parkinson's disease, hydrocephalus, or history
   of significant head trauma.

10. Subjects who use medications to treat airways disease, such as asthma or COPD or have
   any acute respiratory signs/symptoms (e.g., wheezing).

11. Use of any investigational drug within 30 days or 5 half-lives of the investigational
   drug prior to administration of study medication, whichever is longer

12. A history within the past 1 year of drug or alcohol dependence or abuse.

13. Positive urine screen for drugs of abuse at Screening.(positive Cannabis/Cannabinol
   results are acceptable if there is a documented history of stable use for medical
   purposes).

14. Known allergy or hypersensitivity to alprazolam.

15. History of glaucoma.

16. Subjects who currently have an active major psychiatric disorder where changes in
   pharmacotherapy are needed or anticipated during the study.

17. Hypotension (systolic blood pressure ≤90 mm Hg, diastolic blood pressure ≤50 mm Hg),
   or hypertension (systolic blood pressure ≥140 mm Hg, diastolic blood pressure ≥100 mm
   Hg) measured while seated at screening or baseline.

18. Significant hepatic, renal, gastroenterologic, cardiovascular (including ischemic
   heart disease and congestive heart failure), endocrine, neurologic or hematologic
   disease.

19. Subjects who, in the opinion of the Investigator, should not participate in the study
   for any reason, including if there is a question about the stability or capability of
   the subject to comply with the trial requirements.